KR102611447B1 - 박테리아 감염을 치료하는 화합물 및 방법 - Google Patents
박테리아 감염을 치료하는 화합물 및 방법 Download PDFInfo
- Publication number
- KR102611447B1 KR102611447B1 KR1020197035865A KR20197035865A KR102611447B1 KR 102611447 B1 KR102611447 B1 KR 102611447B1 KR 1020197035865 A KR1020197035865 A KR 1020197035865A KR 20197035865 A KR20197035865 A KR 20197035865A KR 102611447 B1 KR102611447 B1 KR 102611447B1
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- mmol
- int
- oxo
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 133
- 208000035143 Bacterial infection Diseases 0.000 title claims description 23
- 208000022362 bacterial infectious disease Diseases 0.000 title claims description 23
- 238000000034 method Methods 0.000 title description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 45
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 87
- -1 silver hydrogen Chemical class 0.000 claims description 86
- 229910052739 hydrogen Inorganic materials 0.000 claims description 68
- 239000001257 hydrogen Substances 0.000 claims description 63
- 229910052757 nitrogen Inorganic materials 0.000 claims description 52
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 41
- 125000000217 alkyl group Chemical group 0.000 claims description 38
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 36
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 33
- 125000000623 heterocyclic group Chemical group 0.000 claims description 31
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 21
- 101710167893 Penicillin-binding protein 3 Proteins 0.000 claims description 18
- 101710146026 Peptidoglycan D,D-transpeptidase FtsI Proteins 0.000 claims description 18
- 150000002431 hydrogen Chemical class 0.000 claims description 18
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 230000001580 bacterial effect Effects 0.000 claims description 13
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 101710202686 Penicillin-sensitive transpeptidase Proteins 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000006413 ring segment Chemical group 0.000 claims description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
- 229910052709 silver Inorganic materials 0.000 claims 2
- 239000004332 silver Substances 0.000 claims 2
- XCUAIINAJCDIPM-XVFCMESISA-N N(4)-hydroxycytidine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=NO)C=C1 XCUAIINAJCDIPM-XVFCMESISA-N 0.000 claims 1
- 229910003827 NRaRb Inorganic materials 0.000 claims 1
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 303
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 259
- 239000011541 reaction mixture Substances 0.000 description 195
- 239000000243 solution Substances 0.000 description 191
- 239000007787 solid Substances 0.000 description 172
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 118
- 235000019439 ethyl acetate Nutrition 0.000 description 112
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 105
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 92
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 88
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 84
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 78
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 66
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 65
- 238000006243 chemical reaction Methods 0.000 description 61
- 239000012043 crude product Substances 0.000 description 57
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 56
- 239000000203 mixture Substances 0.000 description 54
- 239000012044 organic layer Substances 0.000 description 53
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 52
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 52
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 48
- 238000005481 NMR spectroscopy Methods 0.000 description 40
- 239000012267 brine Substances 0.000 description 37
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 37
- 239000000706 filtrate Substances 0.000 description 34
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 34
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- 238000003818 flash chromatography Methods 0.000 description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 28
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 28
- 239000000741 silica gel Substances 0.000 description 27
- 229910002027 silica gel Inorganic materials 0.000 description 27
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 26
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 26
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 24
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 23
- 239000012298 atmosphere Substances 0.000 description 23
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 23
- 239000000758 substrate Substances 0.000 description 23
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 23
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 20
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide-pyridine complex Substances O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 20
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 19
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 19
- 239000003921 oil Substances 0.000 description 19
- 125000001841 imino group Chemical group [H]N=* 0.000 description 16
- 239000000463 material Substances 0.000 description 16
- 238000003756 stirring Methods 0.000 description 15
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- 239000003208 petroleum Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 13
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 13
- 238000010898 silica gel chromatography Methods 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 101710205263 Peptidoglycan D,D-transpeptidase MrdA Proteins 0.000 description 12
- 101710116427 Probable peptidoglycan D,D-transpeptidase PenA Proteins 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 229920006395 saturated elastomer Polymers 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- CVLAEJNQNKXNNN-UHFFFAOYSA-N diazepin-4-one Chemical compound O=C1C=CC=NN=C1 CVLAEJNQNKXNNN-UHFFFAOYSA-N 0.000 description 9
- 239000006260 foam Substances 0.000 description 9
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 235000019270 ammonium chloride Nutrition 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 150000002923 oximes Chemical class 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- QPFYXYFORQJZEC-FOCLMDBBSA-N Phenazopyridine Chemical class NC1=NC(N)=CC=C1\N=N\C1=CC=CC=C1 QPFYXYFORQJZEC-FOCLMDBBSA-N 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- WLLIXJBWWFGEHT-UHFFFAOYSA-N [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate Chemical compound CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F WLLIXJBWWFGEHT-UHFFFAOYSA-N 0.000 description 6
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 229940070891 pyridium Drugs 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 6
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 6
- 210000000689 upper leg Anatomy 0.000 description 6
- LPAONZGJSCSUFD-UHFFFAOYSA-N (9-oxo-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-10-yl) hydrogen sulfate Chemical compound O=C1N(OS(=O)(=O)O)C2CN1CC1=C2C=NN1 LPAONZGJSCSUFD-UHFFFAOYSA-N 0.000 description 5
- IXLVUUFUDRJUSL-RPBOFIJWSA-N 5-[[4-(3-acetamidophenyl)phenyl]methyl]-n-[(1s,2r)-2-phenylcyclopropyl]-1,3-oxazole-4-carboxamide Chemical compound CC(=O)NC1=CC=CC(C=2C=CC(CC3=C(N=CO3)C(=O)N[C@@H]3[C@H](C3)C=3C=CC=CC=3)=CC=2)=C1 IXLVUUFUDRJUSL-RPBOFIJWSA-N 0.000 description 5
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000010933 acylation Effects 0.000 description 5
- 238000005917 acylation reaction Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000012230 colorless oil Substances 0.000 description 5
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 4
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 241000588921 Enterobacteriaceae Species 0.000 description 4
- 241000589602 Francisella tularensis Species 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- KKNKTNXIPXJGFZ-UHFFFAOYSA-N tert-butyl 4-(dimethylaminomethylidene)-3,5-dioxopiperidine-1-carboxylate Chemical compound CN(C)C=C1C(=O)CN(C(=O)OC(C)(C)C)CC1=O KKNKTNXIPXJGFZ-UHFFFAOYSA-N 0.000 description 4
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 4
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- MZAGXDHQGXUDDX-JSRXJHBZSA-N (e,2z)-4-ethyl-2-hydroxyimino-5-nitrohex-3-enamide Chemical group [O-][N+](=O)C(C)C(/CC)=C/C(=N/O)/C(N)=O MZAGXDHQGXUDDX-JSRXJHBZSA-N 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 3
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 3
- ZBLJRQVEMQGYAW-UHFFFAOYSA-N 5-methyl-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-9-one Chemical compound CN1N=CC2=C1CN1CC2NC1=O ZBLJRQVEMQGYAW-UHFFFAOYSA-N 0.000 description 3
- ZSAUCGAVFVWQBK-UHFFFAOYSA-N 5H-1,3-diazepin-6-yl hydrogen sulfate Chemical compound C1C=NC=NC=C1OS(=O)(=O)O ZSAUCGAVFVWQBK-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 241000589291 Acinetobacter Species 0.000 description 3
- 241000588626 Acinetobacter baumannii Species 0.000 description 3
- 241000193738 Bacillus anthracis Species 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- 241000607479 Yersinia pestis Species 0.000 description 3
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 3
- 239000012346 acetyl chloride Substances 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013058 crude material Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 239000003456 ion exchange resin Substances 0.000 description 3
- 229920003303 ion-exchange polymer Polymers 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- SSUCKKNRCOFUPT-UHFFFAOYSA-N o-[tert-butyl(dimethyl)silyl]hydroxylamine Chemical compound CC(C)(C)[Si](C)(C)ON SSUCKKNRCOFUPT-UHFFFAOYSA-N 0.000 description 3
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- RRRAIDHUPSJVHC-FPOVZHCZSA-N (1R,7S)-5-(2-azidoethyl)-N-[tert-butyl(dimethyl)silyl]oxy-N'-methyl-9-oxo-10-phenylmethoxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-diene-7-carboximidamide Chemical compound C\N=C(/NO[Si](C)(C)C(C)(C)C)[C@H]1N2C[C@H](N(OCC3=CC=CC=C3)C2=O)C2=C1N(CCN=[N+]=[N-])N=C2 RRRAIDHUPSJVHC-FPOVZHCZSA-N 0.000 description 2
- NFCZGUUJBPAVRT-HOCLYGCPSA-N (1R,7S)-5-(2-azidoethyl)-N-hydroxy-N'-methyl-9-oxo-10-phenylmethoxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-diene-7-carboximidamide Chemical compound C\N=C(/NO)[C@H]1N2C[C@H](N(OCC3=CC=CC=C3)C2=O)C2=C1N(CCN=[N+]=[N-])N=C2 NFCZGUUJBPAVRT-HOCLYGCPSA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- DOLHGQYGWWLDTI-UHFFFAOYSA-N 1,3-diazepin-5-one Chemical compound O=C1C=CN=CN=C1 DOLHGQYGWWLDTI-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- LYPFMWLZWKNRRA-UHFFFAOYSA-N 4-[(2-methylpropan-2-yl)oxycarbonylamino]butyl methanesulfonate Chemical compound CC(C)(C)OC(=O)NCCCCOS(C)(=O)=O LYPFMWLZWKNRRA-UHFFFAOYSA-N 0.000 description 2
- LXNIACDLPLCQCW-UHFFFAOYSA-N 6-O-tert-butyl 7-O-methyl 4-(phenylmethoxyamino)-2-trityl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridine-6,7-dicarboxylate Chemical compound C(C1=CC=CC=C1)ONC1C=2C(C(N(C1)C(=O)OC(C)(C)C)C(=O)OC)=NN(C=2)C(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 LXNIACDLPLCQCW-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 241001453380 Burkholderia Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 2
- ODBYIMUTLRGAOU-HOCLYGCPSA-N N-[2-[(1R,7S)-7-[N-[tert-butyl(dimethyl)silyl]oxy-N'-methylcarbamimidoyl]-10-hydroxy-9-oxo-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-5-yl]ethyl]acetamide Chemical compound CN\C(=N/O[Si](C)(C)C(C)(C)C)[C@H]1N2C[C@H](N(O)C2=O)C2=C1N(CCNC(C)=O)N=C2 ODBYIMUTLRGAOU-HOCLYGCPSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 101000767160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Intracellular protein transport protein USO1 Proteins 0.000 description 2
- 229910004298 SiO 2 Inorganic materials 0.000 description 2
- 229910020346 SiS 2 Inorganic materials 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- QWKTUZBEVPRNSM-HOCLYGCPSA-N [(1R,7S)-5-(2-acetamidoethyl)-7-[N-[tert-butyl(dimethyl)silyl]oxy-N'-methylcarbamimidoyl]-9-oxo-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-10-yl] hydrogen sulfate Chemical compound S(=O)(=O)(ON1C(N2[C@@H](C3=C([C@@H]1C2)C=NN3CCNC(C)=O)/C(/NC)=N/O[Si](C)(C)C(C)(C)C)=O)O QWKTUZBEVPRNSM-HOCLYGCPSA-N 0.000 description 2
- 229960001171 acetohydroxamic acid Drugs 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 2
- 239000012455 biphasic mixture Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229960003376 levofloxacin Drugs 0.000 description 2
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 2
- RXJQKHLSDKCWNQ-ZFWWWQNUSA-N methyl (1R,7S)-5-methyl-9-oxo-10-phenylmethoxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-diene-7-carboxylate Chemical compound COC(=O)[C@H]1N2C[C@H](N(OCC3=CC=CC=C3)C2=O)C2=C1N(C)N=C2 RXJQKHLSDKCWNQ-ZFWWWQNUSA-N 0.000 description 2
- ZBGNCOJCOITFIE-UHFFFAOYSA-N methyl 1-methyl-4-(phenylmethoxyamino)-4,5,6,7-tetrahydropyrazolo[3,4-c]pyridine-7-carboxylate Chemical compound C(C1=CC=CC=C1)ONC1C2=C(C(NC1)C(=O)OC)N(N=C2)C ZBGNCOJCOITFIE-UHFFFAOYSA-N 0.000 description 2
- VHIGSGMUCCPWFE-UHFFFAOYSA-N methyl 4-(phenylmethoxyamino)-4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c]pyridine-7-carboxylate Chemical compound C12=CNN=C2C(C(=O)OC)NCC1NOCC1=CC=CC=C1 VHIGSGMUCCPWFE-UHFFFAOYSA-N 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000008261 resistance mechanism Effects 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- GVFXQWVQNDXEEL-UHFFFAOYSA-N tert-butyl 1-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-4-hydroxy-5,7-dihydro-4H-pyrazolo[3,4-c]pyridine-6-carboxylate Chemical compound [Si](C)(C)(C(C)(C)C)OCCN1N=CC2=C1CN(CC2O)C(=O)OC(C)(C)C GVFXQWVQNDXEEL-UHFFFAOYSA-N 0.000 description 2
- LTYDJYVNADLXOC-UHFFFAOYSA-N tert-butyl 1-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-4-oxo-5,7-dihydropyrazolo[3,4-c]pyridine-6-carboxylate Chemical compound [Si](C)(C)(C(C)(C)C)OCCN1N=CC2=C1CN(CC2=O)C(=O)OC(C)(C)C LTYDJYVNADLXOC-UHFFFAOYSA-N 0.000 description 2
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 2
- PPMNMHLOYSFMNR-UHFFFAOYSA-N tert-butyl 4-hydroxy-2-trityl-5,7-dihydro-4h-pyrazolo[3,4-c]pyridine-6-carboxylate Chemical compound N1=C2CN(C(=O)OC(C)(C)C)CC(O)C2=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 PPMNMHLOYSFMNR-UHFFFAOYSA-N 0.000 description 2
- FOACYMWDXLSAPQ-UHFFFAOYSA-N tert-butyl 4-oxo-2-trityl-5,7-dihydropyrazolo[3,4-c]pyridine-6-carboxylate Chemical compound O=C1C=2C(CN(C1)C(=O)OC(C)(C)C)=NN(C=2)C(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 FOACYMWDXLSAPQ-UHFFFAOYSA-N 0.000 description 2
- CEJUXSLWIXOHDR-UHFFFAOYSA-N tert-butyl N-[2-(azidomethyl)-1,3-thiazol-4-yl]carbamate Chemical compound N(=[N+]=[N-])CC=1SC=C(N=1)NC(OC(C)(C)C)=O CEJUXSLWIXOHDR-UHFFFAOYSA-N 0.000 description 2
- UMBRACGEFIXIPX-UHFFFAOYSA-N tert-butyl N-[2-(hydroxymethyl)-1,3-thiazol-4-yl]carbamate Chemical compound CC(C)(C)OC(=O)Nc1csc(CO)n1 UMBRACGEFIXIPX-UHFFFAOYSA-N 0.000 description 2
- XFXMITQHWUMNNP-HZMBPMFUSA-N tert-butyl N-[2-[[[(hydroxyamino)-[(1R,7S)-5-methyl-9-oxo-10-sulfooxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-7-yl]methylidene]amino]methyl]-1,3-thiazol-4-yl]carbamate Chemical compound Cn1ncc2[C@@H]3CN([C@H](\C(NO)=N\Cc4nc(NC(=O)OC(C)(C)C)cs4)c12)C(=O)N3OS(O)(=O)=O XFXMITQHWUMNNP-HZMBPMFUSA-N 0.000 description 2
- KAJZZLBZXOBEMD-UHFFFAOYSA-N tert-butyl n-chlorosulfonylcarbamate Chemical compound CC(C)(C)OC(=O)NS(Cl)(=O)=O KAJZZLBZXOBEMD-UHFFFAOYSA-N 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- NVSDADJBGGUCLP-UHFFFAOYSA-N trisulfur Chemical compound S=S=S NVSDADJBGGUCLP-UHFFFAOYSA-N 0.000 description 2
- 239000002132 β-lactam antibiotic Substances 0.000 description 2
- 229940124586 β-lactam antibiotics Drugs 0.000 description 2
- UEITVNRAAYCYFD-CBAPKCEASA-N (1R,7S)-10-hydroxy-N-methoxy-N',5-dimethyl-9-oxo-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-diene-7-carboximidamide Chemical compound CON\C(=N/C)[C@H]1N2C[C@H](N(O)C2=O)C2=C1N(C)N=C2 UEITVNRAAYCYFD-CBAPKCEASA-N 0.000 description 1
- AKRBEKKJUNLZRX-FPOVZHCZSA-N (1R,7S)-5-(2-aminoethyl)-N-[tert-butyl(dimethyl)silyl]oxy-N'-methyl-9-oxo-10-phenylmethoxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-diene-7-carboximidamide Chemical compound C\N=C(/NO[Si](C)(C)C(C)(C)C)[C@H]1N2C[C@H](N(OCC3=CC=CC=C3)C2=O)C2=C1N(CCN)N=C2 AKRBEKKJUNLZRX-FPOVZHCZSA-N 0.000 description 1
- YETXYCRREJHKNJ-LSDHHAIUSA-N (1R,7S)-5-(2-azidoethyl)-9-oxo-10-phenylmethoxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-diene-7-carbaldehyde Chemical compound [N-]=[N+]=NCCN1N=CC2=C1[C@@H](C=O)N1C[C@@H]2N(OCC2=CC=CC=C2)C1=O YETXYCRREJHKNJ-LSDHHAIUSA-N 0.000 description 1
- QQIUKEGIUQPLBY-UONOGXRCSA-N (1R,7S)-5-methyl-9-oxo-10-phenylmethoxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-diene-7-carbaldehyde Chemical compound CN1N=CC2=C1[C@@H](C=O)N1C[C@@H]2N(OCC2=CC=CC=C2)C1=O QQIUKEGIUQPLBY-UONOGXRCSA-N 0.000 description 1
- JLBOQNLXWQEOFZ-UONOGXRCSA-N (1R,7S)-7-(hydroxymethyl)-5-methyl-10-phenylmethoxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-9-one Chemical compound CN1N=CC2=C1[C@@H](CO)N1C[C@@H]2N(OCC2=CC=CC=C2)C1=O JLBOQNLXWQEOFZ-UONOGXRCSA-N 0.000 description 1
- UVTDRXAIXPQKFC-BYCMXARLSA-N (1R,7S)-7-[(1R)-1-hydroxyethyl]-5-methyl-10-phenylmethoxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-9-one Chemical compound C[C@@H](O)[C@H]1N2C[C@H](N(OCC3=CC=CC=C3)C2=O)C2=C1N(C)N=C2 UVTDRXAIXPQKFC-BYCMXARLSA-N 0.000 description 1
- ANQTXOXZKFQKOH-TWZNPMNKSA-N (1R,7S)-7-[5-[[tert-butyl(dimethyl)silyl]oxymethyl]-4,5-dihydro-1,2-oxazol-3-yl]-10-hydroxy-5-methyl-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-9-one Chemical compound CN1N=CC2=C1[C@H](N1C[C@@H]2N(O)C1=O)C1=NOC(CO[Si](C)(C)C(C)(C)C)C1 ANQTXOXZKFQKOH-TWZNPMNKSA-N 0.000 description 1
- RXAUGIOLZQTFPF-DNPUCPKASA-N (1R,7S)-7-[5-[[tert-butyl(dimethyl)silyl]oxymethyl]-4,5-dihydro-1,2-oxazol-3-yl]-5-methyl-10-phenylmethoxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-9-one Chemical compound CN1N=CC2=C1[C@H](N1C[C@@H]2N(OCC2=CC=CC=C2)C1=O)C1=NOC(CO[Si](C)(C)C(C)(C)C)C1 RXAUGIOLZQTFPF-DNPUCPKASA-N 0.000 description 1
- DYCSGFUAKRDCES-AAEUAGOBSA-N (1R,7S)-N-[tert-butyl(dimethyl)silyl]oxy-10-hydroxy-N',5-dimethyl-9-oxo-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-diene-7-carboximidamide Chemical compound C\N=C(/NO[Si](C)(C)C(C)(C)C)[C@H]1N2C[C@H](N(O)C2=O)C2=C1N(C)N=C2 DYCSGFUAKRDCES-AAEUAGOBSA-N 0.000 description 1
- GCFBFGAGEIYDHB-QHZVRINDSA-N (1R,7Z,7S)-N-[tert-butyl(dimethyl)silyl]oxy-5-methyl-9-oxo-10-phenylmethoxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-diene-7-carboximidoyl cyanide Chemical compound C(C1=CC=CC=C1)ON1C(N2[C@@H](C3=C([C@@H]1C2)C=NN3C)/C(=N/O[Si](C)(C)C(C)(C)C)/C#N)=O GCFBFGAGEIYDHB-QHZVRINDSA-N 0.000 description 1
- YZOQHJMBUVLKTN-JUIRDXJGSA-N (1R,7Z,7S)-N-hydroxy-5-methyl-9-oxo-10-phenylmethoxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-diene-7-carboximidoyl chloride Chemical compound Cn1ncc2[C@@H]3CN([C@H](\C(Cl)=N\O)c12)C(=O)N3OCc1ccccc1 YZOQHJMBUVLKTN-JUIRDXJGSA-N 0.000 description 1
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- FZENGILVLUJGJX-IHWYPQMZSA-N (Z)-acetaldehyde oxime Chemical compound C\C=N/O FZENGILVLUJGJX-IHWYPQMZSA-N 0.000 description 1
- HQDYNFWTFJFEPR-UHFFFAOYSA-N 1,2,3,3a-tetrahydropyrene Chemical compound C1=C2CCCC(C=C3)C2=C2C3=CC=CC2=C1 HQDYNFWTFJFEPR-UHFFFAOYSA-N 0.000 description 1
- VVSASNKOFCZVES-UHFFFAOYSA-N 1,3-dimethyl-1,3-diazinane-2,4,6-trione Chemical compound CN1C(=O)CC(=O)N(C)C1=O VVSASNKOFCZVES-UHFFFAOYSA-N 0.000 description 1
- RYZCOJFLAFWWBQ-UHFFFAOYSA-N 1-(2-hydroxyethyl)-4-oxo-5,7-dihydropyrazolo[3,4-c]pyridine-6-carboxylic acid Chemical compound OCCn1ncc2c1CN(CC2=O)C(O)=O RYZCOJFLAFWWBQ-UHFFFAOYSA-N 0.000 description 1
- FIGWHZAZVQJDNF-UHFFFAOYSA-N 1-methyl-6-[(2-methylpropan-2-yl)oxycarbonyl]-4-oxo-5,7-dihydropyrazolo[3,4-c]pyridine-7-carboxylic acid Chemical compound C(C)(C)(C)OC(=O)N1C(C2=C(C(C1)=O)C=NN2C)C(=O)O FIGWHZAZVQJDNF-UHFFFAOYSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- KLODVYMBDVDDLC-UHFFFAOYSA-N 2,3-dioxopiperazine-1-carboxamide Chemical compound NC(=O)N1CCNC(=O)C1=O KLODVYMBDVDDLC-UHFFFAOYSA-N 0.000 description 1
- ZZZSOTOZBJNEMF-BBRMVZONSA-N 2-[(1R,7S)-7-(N-hydroxy-N'-methylcarbamimidoyl)-9-oxo-10-phenylmethoxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-5-yl]acetic acid Chemical compound CN\C(=N/O)[C@H]1N2C[C@H](N(OCC3=CC=CC=C3)C2=O)C2=C1N(CC(O)=O)N=C2 ZZZSOTOZBJNEMF-BBRMVZONSA-N 0.000 description 1
- QQDCXQURAAVVHQ-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl methanesulfonate Chemical compound CC(C)(C)OC(=O)NCCOS(C)(=O)=O QQDCXQURAAVVHQ-UHFFFAOYSA-N 0.000 description 1
- OLZIMVRPDCVKLL-XVKPBYJWSA-N 2-[[C-[(1R,7S)-10-hydroxy-5-methyl-9-oxo-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-7-yl]-N-methylcarbonimidoyl]amino]oxyacetamide Chemical compound ON1C(N2[C@@H](C3=C([C@@H]1C2)C=NN3C)/C(/NC)=N/OCC(=O)N)=O OLZIMVRPDCVKLL-XVKPBYJWSA-N 0.000 description 1
- WIUKEUCTGKKKHH-YOEHRIQHSA-N 2-[[N-methyl-C-[(1R,7S)-5-methyl-9-oxo-10-phenylmethoxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-7-yl]carbonimidoyl]amino]oxyacetamide Chemical compound CN\C(=N/OCC(N)=O)[C@H]1N2C[C@H](N(OCC3=CC=CC=C3)C2=O)C2=C1N(C)N=C2 WIUKEUCTGKKKHH-YOEHRIQHSA-N 0.000 description 1
- RCQJLZGMPPKUAB-YOEHRIQHSA-N 2-[[N-methyl-C-[(1R,7S)-5-methyl-9-oxo-10-phenylmethoxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-7-yl]carbonimidoyl]amino]oxyacetic acid Chemical compound CN\C(=N/OCC(O)=O)[C@H]1N2C[C@H](N(OCC3=CC=CC=C3)C2=O)C2=C1N(C)N=C2 RCQJLZGMPPKUAB-YOEHRIQHSA-N 0.000 description 1
- JUIKUQOUMZUFQT-UHFFFAOYSA-N 2-bromoacetamide Chemical compound NC(=O)CBr JUIKUQOUMZUFQT-UHFFFAOYSA-N 0.000 description 1
- GBHCABUWWQUMAJ-UHFFFAOYSA-N 2-hydrazinoethanol Chemical compound NNCCO GBHCABUWWQUMAJ-UHFFFAOYSA-N 0.000 description 1
- HMDOHALMCRHCFZ-UHFFFAOYSA-N 2-nitro-n-phenylmethoxybenzenesulfonamide Chemical compound [O-][N+](=O)C1=CC=CC=C1S(=O)(=O)NOCC1=CC=CC=C1 HMDOHALMCRHCFZ-UHFFFAOYSA-N 0.000 description 1
- DAMLJSHNUGUIGT-UHFFFAOYSA-N 4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-1(10),2,4,6-tetraene-7-carboxylic acid Chemical compound C1C2=NCN1C(=C3C2=CN=N3)C(=O)O DAMLJSHNUGUIGT-UHFFFAOYSA-N 0.000 description 1
- JPSGFNBHAYOLEK-UHFFFAOYSA-N 4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-1,3,6-trien-10-yl hydrogen sulfate Chemical compound S(=O)(=O)(O)ON1CN2C=C3C(=C1C2)C=NN3 JPSGFNBHAYOLEK-UHFFFAOYSA-N 0.000 description 1
- MELUQKLYNOBGHT-RDJZCZTQSA-N 4,6,6-trimethyl-3-[(1R,7S)-5-methyl-9-oxo-10-phenylmethoxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-7-yl]-1,2,4-oxadiazin-5-one Chemical compound CN1N=CC2=C1[C@H](N1C[C@@H]2N(OCC2=CC=CC=C2)C1=O)C1=NOC(C)(C)C(=O)N1C MELUQKLYNOBGHT-RDJZCZTQSA-N 0.000 description 1
- SXVBQOZRZIUHKU-UHFFFAOYSA-N 4-ethyl-2,3-dioxopiperazine-1-carbonyl chloride Chemical compound CCN1CCN(C(Cl)=O)C(=O)C1=O SXVBQOZRZIUHKU-UHFFFAOYSA-N 0.000 description 1
- ZVUDPIBVNIMXAV-ZVBGSRNCSA-N 5-(2-azidoethyl)-7-[(E)-hydroxyiminomethyl]-10-phenylmethoxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-9-one Chemical compound N(=[N+]=[N-])CCN1N=CC2=C1C(N1C(N(C2C1)OCC1=CC=CC=C1)=O)/C=N/O ZVUDPIBVNIMXAV-ZVBGSRNCSA-N 0.000 description 1
- HLTCRYWHCQNGPA-XQNSMLJCSA-N 6-O-tert-butyl 7-O-methyl (4Z)-1-methyl-4-phenylmethoxyimino-5,7-dihydropyrazolo[3,4-c]pyridine-6,7-dicarboxylate Chemical compound COC(=O)C1N(C\C(=N/OCC2=CC=CC=C2)C2=C1N(C)N=C2)C(=O)OC(C)(C)C HLTCRYWHCQNGPA-XQNSMLJCSA-N 0.000 description 1
- RIIKHAJMPRLNCC-UHFFFAOYSA-N 6-O-tert-butyl 7-O-methyl 1-methyl-4-oxo-5,7-dihydropyrazolo[3,4-c]pyridine-6,7-dicarboxylate Chemical compound COC(=O)C1N(CC(=O)C2=C1N(C)N=C2)C(=O)OC(C)(C)C RIIKHAJMPRLNCC-UHFFFAOYSA-N 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000004020 Brain Abscess Diseases 0.000 description 1
- 206010051548 Burn infection Diseases 0.000 description 1
- CYHBHDPBLIQMGV-UHFFFAOYSA-N C\N=C(/NO[Si](C)(C)C(C)(C)C)C1N2CC(N(OCC3=CC=CC=C3)C2=O)C2=C1N(C)N=C2 Chemical compound C\N=C(/NO[Si](C)(C)C(C)(C)C)C1N2CC(N(OCC3=CC=CC=C3)C2=O)C2=C1N(C)N=C2 CYHBHDPBLIQMGV-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108010054814 DNA Gyrase Proteins 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102000008016 Eukaryotic Initiation Factor-3 Human genes 0.000 description 1
- 108010089790 Eukaryotic Initiation Factor-3 Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 229910021617 Indium monochloride Inorganic materials 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100446506 Mus musculus Fgf3 gene Proteins 0.000 description 1
- 101100348848 Mus musculus Notch4 gene Proteins 0.000 description 1
- 101100317378 Mus musculus Wnt3 gene Proteins 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- KSUMBEBYQWGJEY-UHFFFAOYSA-N N-[1-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-4,5,6,7-tetrahydropyrazolo[3,4-c]pyridin-4-yl]-4-nitro-N-phenylmethoxybenzenesulfonamide Chemical compound C(C1=CC=CC=C1)ON(S(=O)(=O)C1=CC=C(C=C1)[N+](=O)[O-])C1C2=C(CNC1)N(N=C2)CCO[Si](C)(C)C(C)(C)C KSUMBEBYQWGJEY-UHFFFAOYSA-N 0.000 description 1
- SCEGRDBWXYBBDU-UHFFFAOYSA-N N-[1-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-4,5-dihydropyrazolo[3,4-c]pyridin-4-yl]-4-nitro-N-phenylmethoxybenzenesulfonamide Chemical compound C(C1=CC=CC=C1)ON(S(=O)(=O)C1=CC=C(C=C1)[N+](=O)[O-])C1C2=C(C=NC1)N(N=C2)CCO[Si](C)(C)C(C)(C)C SCEGRDBWXYBBDU-UHFFFAOYSA-N 0.000 description 1
- HUFAOPSONYFPMF-UHFFFAOYSA-N N-[1-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-7-cyano-4,5,6,7-tetrahydropyrazolo[3,4-c]pyridin-4-yl]-4-nitro-N-phenylmethoxybenzenesulfonamide Chemical compound C(C1=CC=CC=C1)ON(S(=O)(=O)C1=CC=C(C=C1)[N+](=O)[O-])C1C2=C(C(NC1)C#N)N(N=C2)CCO[Si](C)(C)C(C)(C)C HUFAOPSONYFPMF-UHFFFAOYSA-N 0.000 description 1
- WXMWNILRMRYBNF-GMAHTHKFSA-N N-[2-[(1R,7S)-7-[N-[tert-butyl(dimethyl)silyl]oxy-N'-methylcarbamimidoyl]-9-oxo-10-phenylmethoxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-5-yl]ethyl]acetamide Chemical compound CN\C(=N/O[Si](C)(C)C(C)(C)C)[C@H]1N2C[C@H](N(OCC3=CC=CC=C3)C2=O)C2=C1N(CCNC(C)=O)N=C2 WXMWNILRMRYBNF-GMAHTHKFSA-N 0.000 description 1
- LSKKZWWIRFHPTC-LPHOPBHVSA-N N-[tert-butyl(dimethyl)silyl]-2-[(1R,7S)-7-[N-[tert-butyl(dimethyl)silyl]oxy-N'-methylcarbamimidoyl]-10-hydroxy-9-oxo-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-5-yl]acetamide Chemical compound CN\C(=N/O[Si](C)(C)C(C)(C)C)[C@H]1N2C[C@H](N(O)C2=O)C2=C1N(CC(=O)N[Si](C)(C)C(C)(C)C)N=C2 LSKKZWWIRFHPTC-LPHOPBHVSA-N 0.000 description 1
- DBYUSKYKPWHHJA-UHFFFAOYSA-N N-hydroxy-N',5-dimethyl-9-oxo-10-phenylmethoxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-diene-7-carboximidamide Chemical compound C\N=C(/NO)C1N2CC(N(OCC3=CC=CC=C3)C2=O)C2=C1N(C)N=C2 DBYUSKYKPWHHJA-UHFFFAOYSA-N 0.000 description 1
- AEKUZHSNQRLULL-AAEUAGOBSA-N N1([C@H]2CN(C1=O)[C@@H](C=1NN=CC=12)C(=O)O)OCC1=CC=CC=C1 Chemical compound N1([C@H]2CN(C1=O)[C@@H](C=1NN=CC=12)C(=O)O)OCC1=CC=CC=C1 AEKUZHSNQRLULL-AAEUAGOBSA-N 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- JCSFNLUCBSWZIW-UHFFFAOYSA-N O=C1N(OS(O)(=O)=O)C2CN1CC1=C2C=NN1C Chemical compound O=C1N(OS(O)(=O)=O)C2CN1CC1=C2C=NN1C JCSFNLUCBSWZIW-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108700020474 Penicillin-Binding Proteins Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 108010013381 Porins Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000122971 Stenotrophomonas Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- MQRWVCIXLQAMCS-ZSOXZCCMSA-N [(1R)-5-(2-amino-2-oxoethyl)-7-[N-[tert-butyl(dimethyl)silyl]oxy-N'-methylcarbamimidoyl]-9-oxo-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-10-yl] hydrogen sulfate Chemical compound S(=O)(=O)(ON1C(N2C(C3=C([C@@H]1C2)C=NN3CC(=O)N)/C(/NC)=N/O[Si](C)(C)C(C)(C)C)=O)O MQRWVCIXLQAMCS-ZSOXZCCMSA-N 0.000 description 1
- MXOHVCMVKCVGPH-XPUUQOCRSA-N [(1R,7S)-5-methyl-7-(4-methyl-5-oxo-1,2,4-oxadiazol-3-yl)-9-oxo-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-10-yl] hydrogen sulfate Chemical compound Cn1ncc2[C@@H]3CN([C@H](c4noc(=O)n4C)c12)C(=O)N3OS(O)(=O)=O MXOHVCMVKCVGPH-XPUUQOCRSA-N 0.000 description 1
- PDOHHLHGQXCHAE-XPUUQOCRSA-N [(1R,7S)-5-methyl-7-(N'-methyl-N-sulfamoyloxycarbamimidoyl)-9-oxo-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-10-yl] hydrogen sulfate Chemical compound C\N=C(/NOS(N)(=O)=O)[C@H]1N2C[C@H](N(OS(O)(=O)=O)C2=O)c2cnn(C)c12 PDOHHLHGQXCHAE-XPUUQOCRSA-N 0.000 description 1
- MQZMNZTZLJOLLL-MKFCGFABSA-N [(1R,7S)-7-[(Z)-N'-hydroxy-N,N-dimethylcarbamimidoyl]-5-methyl-9-oxo-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-10-yl] hydrogen sulfate Chemical compound CN(C)C(=N/O)\[C@H]1N2C[C@H](N(OS(O)(=O)=O)C2=O)c2cnn(C)c12 MQZMNZTZLJOLLL-MKFCGFABSA-N 0.000 description 1
- LKSYGBGWDFURIG-CPCISQLKSA-N [(1R,7S)-7-[4-[(4-amino-1,3-thiazol-2-yl)methyl]-5-oxo-1,2,4-oxadiazol-3-yl]-5-methyl-9-oxo-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-10-yl] hydrogen sulfate Chemical compound Cn1ncc2[C@@H]3CN([C@H](c4noc(=O)n4Cc4nc(N)cs4)c12)C(=O)N3OS(O)(=O)=O LKSYGBGWDFURIG-CPCISQLKSA-N 0.000 description 1
- PWTBRXYGZXNAAI-FVKKKHHLSA-N [(1R,7S)-7-[5-(hydroxymethyl)-4-methyl-4,5-dihydro-1,2-oxazol-3-yl]-5-methyl-9-oxo-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-10-yl] hydrogen sulfate Chemical compound CC1C(CO)ON=C1[C@H]1N2C[C@H](N(OS(O)(=O)=O)C2=O)c2cnn(C)c12 PWTBRXYGZXNAAI-FVKKKHHLSA-N 0.000 description 1
- PKJYAFSTYYYUGG-AAEUAGOBSA-N [(1R,7S)-7-[N-[tert-butyl(dimethyl)silyl]oxy-N'-methylcarbamimidoyl]-5-methyl-9-oxo-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-10-yl] hydrogen sulfate Chemical compound S(=O)(=O)(ON1C(N2[C@@H](C3=C([C@@H]1C2)C=NN3C)/C(/NC)=N/O[Si](C)(C)C(C)(C)C)=O)O PKJYAFSTYYYUGG-AAEUAGOBSA-N 0.000 description 1
- AHHANBLWGYUCMT-ZNTXYYKOSA-N [(Z)-[[carbamoyl(methyl)amino]-[(1R,7S)-5-methyl-9-oxo-10-sulfooxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-7-yl]methylidene]amino] N-[2-(carbamoylamino)ethyl]carbamate Chemical compound CN(C(N)=O)C(=N/OC(=O)NCCNC(N)=O)\[C@H]1N2C[C@H](N(OS(O)(=O)=O)C2=O)c2cnn(C)c12 AHHANBLWGYUCMT-ZNTXYYKOSA-N 0.000 description 1
- HYRCOFARQHMMPT-CBAPKCEASA-N [(Z)-[amino-[(1R,7S)-5-methyl-9-oxo-10-sulfooxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-7-yl]methylidene]amino] acetate Chemical compound S(=O)(=O)(ON1C(N2[C@@H](C3=C([C@@H]1C2)C=NN3C)/C(/N)=N/OC(C)=O)=O)O HYRCOFARQHMMPT-CBAPKCEASA-N 0.000 description 1
- DVTSDGWMAYKVJI-UHFFFAOYSA-N [4-[(2-methylpropan-2-yl)oxycarbonylamino]-1,3-thiazol-2-yl]methyl methanesulfonate Chemical compound CS(=O)(=O)OCC=1SC=C(N=1)NC(=O)OC(C)(C)C DVTSDGWMAYKVJI-UHFFFAOYSA-N 0.000 description 1
- XIZCEXLTERXKPV-IJUHEHPCSA-N [5-[(2E)-2-(2-aminoethoxyimino)ethyl]-7-(N-hydroxy-N'-methylcarbamimidoyl)-9-oxo-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-10-yl] hydrogen sulfate Chemical compound C\N=C(/NO)C1N2CC(N(OS(O)(=O)=O)C2=O)c2cnn(C\C=N\OCCN)c12 XIZCEXLTERXKPV-IJUHEHPCSA-N 0.000 description 1
- ZSJSUGQFCVLMIX-WPRPVWTQSA-N [[C-[(1R,7S)-10-hydroxy-5-methyl-9-oxo-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-7-yl]-N-methylcarbonimidoyl]amino] acetate Chemical compound C\N=C(/NOC(C)=O)[C@H]1N2C[C@H](N(O)C2=O)C2=C1N(C)N=C2 ZSJSUGQFCVLMIX-WPRPVWTQSA-N 0.000 description 1
- SFOIVKGXSGEMLJ-XPUUQOCRSA-N [[C-[(1R,7S)-10-hydroxy-5-methyl-9-oxo-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-7-yl]-N-methylcarbonimidoyl]amino] carbamate Chemical compound C\N=C(/NOC(N)=O)[C@H]1N2C[C@H](N(O)C2=O)C2=C1N(C)N=C2 SFOIVKGXSGEMLJ-XPUUQOCRSA-N 0.000 description 1
- UIVFVMNMVOITHU-ZFWWWQNUSA-N [[N-methyl-C-[(1R,7S)-5-methyl-9-oxo-10-phenylmethoxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-7-yl]carbonimidoyl]amino] carbamate Chemical compound C\N=C(/NOC(N)=O)[C@H]1N2C[C@H](N(OCC3=CC=CC=C3)C2=O)C2=C1N(C)N=C2 UIVFVMNMVOITHU-ZFWWWQNUSA-N 0.000 description 1
- SVMNHORIQKWSSE-WPRPVWTQSA-N [[N-methyl-C-[(1R,7S)-5-methyl-9-oxo-10-sulfooxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-7-yl]carbonimidoyl]amino] N-[2-(carbamoylamino)ethyl]carbamate Chemical compound C\N=C(/NOC(=O)NCCNC(N)=O)[C@H]1N2C[C@H](N(OS(O)(=O)=O)C2=O)c2cnn(C)c12 SVMNHORIQKWSSE-WPRPVWTQSA-N 0.000 description 1
- WIGRWXCKSVXWRZ-JQWIXIFHSA-N [[N-methyl-C-[(1R,7S)-5-methyl-9-oxo-10-sulfooxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-7-yl]carbonimidoyl]amino] N-[4-[(2,2,2-trifluoroacetyl)amino]butyl]carbamate Chemical compound S(=O)(=O)(ON1C(N2[C@@H](C3=C([C@@H]1C2)C=NN3C)/C(/NC)=N/OC(NCCCCNC(C(F)(F)F)=O)=O)=O)O WIGRWXCKSVXWRZ-JQWIXIFHSA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- NNTOJPXOCKCMKR-UHFFFAOYSA-N boron;pyridine Chemical compound [B].C1=CC=NC=C1 NNTOJPXOCKCMKR-UHFFFAOYSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 238000002815 broth microdilution Methods 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-O butylazanium Chemical compound CCCC[NH3+] HQABUPZFAYXKJW-UHFFFAOYSA-O 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 108010068385 carbapenemase Proteins 0.000 description 1
- OWIUPIRUAQMTTK-UHFFFAOYSA-N carbazic acid Chemical compound NNC(O)=O OWIUPIRUAQMTTK-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical class [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940068911 chloride hexahydrate Drugs 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 1
- VVHZEOFICMARAV-UHFFFAOYSA-N chlorosulfonylcarbamic acid Chemical compound OC(=O)NS(Cl)(=O)=O VVHZEOFICMARAV-UHFFFAOYSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005048 dihydroisoxazolyl group Chemical group O1N(CC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005053 dihydropyrimidinyl group Chemical group N1(CN=CC=C1)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 208000010227 enterocolitis Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000000198 fluorescence anisotropy Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 229940118764 francisella tularensis Drugs 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 244000000058 gram-negative pathogen Species 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- VOAPTKOANCCNFV-UHFFFAOYSA-N hexahydrate;hydrochloride Chemical compound O.O.O.O.O.O.Cl VOAPTKOANCCNFV-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- APHGZSBLRQFRCA-UHFFFAOYSA-M indium(1+);chloride Chemical compound [In]Cl APHGZSBLRQFRCA-UHFFFAOYSA-M 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- NIZHERJWXFHGGU-UHFFFAOYSA-N isocyanato(trimethyl)silane Chemical compound C[Si](C)(C)N=C=O NIZHERJWXFHGGU-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 1
- SIHOCRYRHWNYDC-XPUUQOCRSA-N methyl (1R,7S)-10-hydroxy-5-methyl-9-oxo-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-diene-7-carboxylate Chemical compound COC(=O)[C@H]1N2C[C@H](N(O)C2=O)C2=C1N(C)N=C2 SIHOCRYRHWNYDC-XPUUQOCRSA-N 0.000 description 1
- PCAYUZJIIVJQNV-LPHOPBHVSA-N methyl (1R,7S)-4-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]-9-oxo-10-phenylmethoxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2,5-diene-7-carboxylate Chemical compound COC(=O)[C@H]1N2C[C@H](N(OCC3=CC=CC=C3)C2=O)C2=CN(CC(=O)OC(C)(C)C)N=C12 PCAYUZJIIVJQNV-LPHOPBHVSA-N 0.000 description 1
- LPTPPVKZCJZNRD-BBRMVZONSA-N methyl (1R,7S)-5-(2,2-dihydroxyethyl)-9-oxo-10-phenylmethoxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-diene-7-carboxylate Chemical compound COC(=O)[C@H]1N2C[C@H](N(OCC3=CC=CC=C3)C2=O)C2=C1N(CC(O)O)N=C2 LPTPPVKZCJZNRD-BBRMVZONSA-N 0.000 description 1
- SOHKRNVJOBMPEH-HOCLYGCPSA-N methyl (1R,7S)-5-(2-azidoethyl)-9-oxo-10-phenylmethoxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-diene-7-carboxylate Chemical compound COC(=O)[C@H]1N2C[C@H](N(OCC3=CC=CC=C3)C2=O)C2=C1N(CCN=[N+]=[N-])N=C2 SOHKRNVJOBMPEH-HOCLYGCPSA-N 0.000 description 1
- YSEIIPXDAAJQSY-HOCLYGCPSA-N methyl (1R,7S)-5-(2-hydroxyethyl)-9-oxo-10-phenylmethoxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-diene-7-carboxylate Chemical compound COC(=O)[C@H]1N2C[C@H](N(OCC3=CC=CC=C3)C2=O)C2=C1N(CCO)N=C2 YSEIIPXDAAJQSY-HOCLYGCPSA-N 0.000 description 1
- DESVTLBFXBWPQT-HBYGCAHESA-N methyl (1R,7S)-5-[(2E)-2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethoxyimino]ethyl]-9-oxo-10-phenylmethoxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-diene-7-carboxylate Chemical compound COC(=O)[C@H]1N2C[C@H](N(OCC3=CC=CC=C3)C2=O)C2=C1N(C\C=N\OCCNC(=O)OC(C)(C)C)N=C2 DESVTLBFXBWPQT-HBYGCAHESA-N 0.000 description 1
- JAHMYTCFGYQNOI-LPHOPBHVSA-N methyl (1R,7S)-5-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]-9-oxo-10-phenylmethoxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-diene-7-carboxylate Chemical compound COC(=O)[C@H]1N2C[C@H](N(OCC3=CC=CC=C3)C2=O)C2=C1N(CC(=O)OC(C)(C)C)N=C2 JAHMYTCFGYQNOI-LPHOPBHVSA-N 0.000 description 1
- KGYPNQVFVXVPTK-FPOVZHCZSA-N methyl (1R,7S)-5-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-9-oxo-10-phenylmethoxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-diene-7-carboxylate Chemical compound COC(=O)[C@H]1N2C[C@H](N(OCC3=CC=CC=C3)C2=O)C2=C1N(CCO[Si](C)(C)C(C)(C)C)N=C2 KGYPNQVFVXVPTK-FPOVZHCZSA-N 0.000 description 1
- IWPCQGPCMBPBPB-UHFFFAOYSA-N methyl 1-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-4-(phenylmethoxyamino)-4,5,6,7-tetrahydropyrazolo[3,4-c]pyridine-7-carboxylate Chemical compound C(C1=CC=CC=C1)ONC1C2=C(C(NC1)C(=O)OC)N(N=C2)CCO[Si](C)(C)C(C)(C)C IWPCQGPCMBPBPB-UHFFFAOYSA-N 0.000 description 1
- MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical compound ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- XYEOALKITRFCJJ-UHFFFAOYSA-N o-benzylhydroxylamine Chemical compound NOCC1=CC=CC=C1 XYEOALKITRFCJJ-UHFFFAOYSA-N 0.000 description 1
- HYDZPXNVHXJHBG-UHFFFAOYSA-N o-benzylhydroxylamine;hydron;chloride Chemical compound Cl.NOCC1=CC=CC=C1 HYDZPXNVHXJHBG-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 206010033072 otitis externa Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 102000007739 porin activity proteins Human genes 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- XHYWMVNYSCWYDT-UHFFFAOYSA-N pyrazolo[3,4-e][1,3]diazepine-8-carboxylic acid Chemical compound C1=C2C=NN=C2C(=NC=N1)C(=O)O XHYWMVNYSCWYDT-UHFFFAOYSA-N 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000004929 pyrrolidonyl group Chemical group N1(C(CCC1)=O)* 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- BABPEPRNSRIYFA-UHFFFAOYSA-N silyl trifluoromethanesulfonate Chemical compound FC(F)(F)S(=O)(=O)O[SiH3] BABPEPRNSRIYFA-UHFFFAOYSA-N 0.000 description 1
- DENRJGZATCJYJD-QMGYSKNISA-M sodium [(1R,7S)-7-(N-hydroxy-N'-methylcarbamimidoyl)-5-methyl-9-oxo-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-10-yl] sulfate Chemical compound [Na+].CN\C(=N/O)[C@H]1N2C[C@H](N(OS([O-])(=O)=O)C2=O)C2=C1N(C)N=C2 DENRJGZATCJYJD-QMGYSKNISA-M 0.000 description 1
- KKWIUAGPVNYJOW-KQBMADMWSA-M sodium [(1R,7S)-7-[(Z)-N'-hydroxycarbamimidoyl]-5-methyl-9-oxo-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-10-yl] sulfate Chemical compound [Na+].CN1N=CC2=C1[C@H](N1C[C@@H]2N(OS([O-])(=O)=O)C1=O)C(\N)=N\O KKWIUAGPVNYJOW-KQBMADMWSA-M 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000004808 supercritical fluid chromatography Methods 0.000 description 1
- GWXBFNDBHVWCCY-UHFFFAOYSA-N tert-butyl 1-(2-hydroxyethyl)-4-oxo-5,7-dihydropyrazolo[3,4-c]pyridine-6-carboxylate Chemical compound CC(C)(C)OC(=O)N1Cc2c(cnn2CCO)C(=O)C1 GWXBFNDBHVWCCY-UHFFFAOYSA-N 0.000 description 1
- SDDNHCVVOSYLCT-UHFFFAOYSA-N tert-butyl 1-methyl-4-oxo-5,7-dihydropyrazolo[3,4-c]pyridine-6-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC(=O)C2=C1N(C)N=C2 SDDNHCVVOSYLCT-UHFFFAOYSA-N 0.000 description 1
- BAQWEFLNJVCONF-URXFXBBRSA-N tert-butyl 2-[(1R,7S)-7-[N-[tert-butyl(dimethyl)silyl]oxy-N'-methylcarbamimidoyl]-9-oxo-10-phenylmethoxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-5-yl]acetate Chemical compound CN\C(=N/O[Si](C)(C)C(C)(C)C)[C@H]1N2C[C@H](N(OCC3=CC=CC=C3)C2=O)C2=C1N(CC(=O)OC(C)(C)C)N=C2 BAQWEFLNJVCONF-URXFXBBRSA-N 0.000 description 1
- QPXVOXBBZSXVQP-PXNSSMCTSA-N tert-butyl 2-[[N-methyl-C-[(1R,7S)-5-methyl-9-oxo-10-phenylmethoxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-7-yl]carbonimidoyl]amino]oxyacetate Chemical compound CN\C(=N/OCC(=O)OC(C)(C)C)[C@H]1N2C[C@H](N(OCC3=CC=CC=C3)C2=O)C2=C1N(C)N=C2 QPXVOXBBZSXVQP-PXNSSMCTSA-N 0.000 description 1
- IGVNJALYNQVQIT-UHFFFAOYSA-N tert-butyl 2-bromo-2-methylpropanoate Chemical compound CC(C)(C)OC(=O)C(C)(C)Br IGVNJALYNQVQIT-UHFFFAOYSA-N 0.000 description 1
- KWNDKZADLGFSKE-UHFFFAOYSA-N tert-butyl 3,5-dioxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(=O)CC(=O)C1 KWNDKZADLGFSKE-UHFFFAOYSA-N 0.000 description 1
- CQJIUOSNROVOKO-UHFFFAOYSA-N tert-butyl 4-hydrazinylidene-5,7-dihydro-1H-pyrazolo[3,4-c]pyridine-6-carboxylate Chemical compound N(N)=C1C=2C(CN(C1)C(=O)OC(C)(C)C)=NNC=2 CQJIUOSNROVOKO-UHFFFAOYSA-N 0.000 description 1
- CVZHZXNTNPPKKB-UHFFFAOYSA-N tert-butyl 4-oxo-5,7-dihydro-1H-pyrazolo[3,4-c]pyridine-6-carboxylate Chemical compound O=C1C2=C(CN(C1)C(=O)OC(C)(C)C)NN=C2 CVZHZXNTNPPKKB-UHFFFAOYSA-N 0.000 description 1
- KRKAMILWOHNWBO-UHFFFAOYSA-N tert-butyl N-(2-formyl-1,3-thiazol-4-yl)carbamate Chemical compound CC(C)(C)OC(=O)Nc1csc(C=O)n1 KRKAMILWOHNWBO-UHFFFAOYSA-N 0.000 description 1
- RIAAUVDMJNUULM-UHFFFAOYSA-N tert-butyl N-[2-(aminomethyl)-1,3-thiazol-4-yl]carbamate Chemical compound NCC=1SC=C(N=1)NC(OC(C)(C)C)=O RIAAUVDMJNUULM-UHFFFAOYSA-N 0.000 description 1
- TXPLJSKVSPTWOM-JQWIXIFHSA-N tert-butyl N-[2-[(1R,7S)-7-(N-hydroxy-N'-methylcarbamimidoyl)-9-oxo-10-sulfooxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-5-yl]ethyl]carbamate Chemical compound C\N=C(/NO)[C@H]1N2C[C@H](N(OS(O)(=O)=O)C2=O)c2cnn(CCNC(=O)OC(C)(C)C)c12 TXPLJSKVSPTWOM-JQWIXIFHSA-N 0.000 description 1
- RZDWUPHZMZHLML-RDJZCZTQSA-N tert-butyl N-[2-[(1R,7S)-7-[N-[tert-butyl(dimethyl)silyl]oxy-N'-methylcarbamimidoyl]-10-hydroxy-9-oxo-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-5-yl]ethyl]carbamate Chemical compound CN\C(=N/O[Si](C)(C)C(C)(C)C)[C@H]1N2C[C@H](N(O)C2=O)C2=C1N(CCNC(=O)OC(C)(C)C)N=C2 RZDWUPHZMZHLML-RDJZCZTQSA-N 0.000 description 1
- GKTZKVREMQIOFL-UPVQGACJSA-N tert-butyl N-[2-[(1R,7S)-7-[N-[tert-butyl(dimethyl)silyl]oxy-N'-methylcarbamimidoyl]-9-oxo-10-phenylmethoxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-5-yl]ethyl]carbamate Chemical compound CN\C(=N/O[Si](C)(C)C(C)(C)C)[C@H]1N2C[C@H](N(OCC3=CC=CC=C3)C2=O)C2=C1N(CCNC(=O)OC(C)(C)C)N=C2 GKTZKVREMQIOFL-UPVQGACJSA-N 0.000 description 1
- RPYOQUBPOUXUSR-JSGCOSHPSA-N tert-butyl N-[4-[(1R,7S)-7-(N-hydroxy-N'-methylcarbamimidoyl)-9-oxo-10-sulfooxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-5-yl]butyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCCN1C2=C(C=N1)[C@@H]3CN([C@@H]2C(=NC)NO)C(=O)N3OS(=O)(=O)O RPYOQUBPOUXUSR-JSGCOSHPSA-N 0.000 description 1
- GQGOORHFXKVEQC-ONGXEEELSA-N tert-butyl N-[[C-[(1R,7S)-10-hydroxy-5-methyl-9-oxo-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-7-yl]-N-methylcarbonimidoyl]amino]oxysulfonylcarbamate Chemical compound CN\C(=N/OS(=O)(=O)NC(=O)OC(C)(C)C)[C@H]1N2C[C@H](N(O)C2=O)C2=C1N(C)N=C2 GQGOORHFXKVEQC-ONGXEEELSA-N 0.000 description 1
- HCDHEWBZUSMJNL-WMZOPIPTSA-N tert-butyl N-[[N-methyl-C-[(1R,7S)-5-methyl-9-oxo-10-phenylmethoxy-4,5,8,10-tetrazatricyclo[6.2.1.02,6]undeca-2(6),3-dien-7-yl]carbonimidoyl]amino]oxysulfonylcarbamate Chemical compound C(C1=CC=CC=C1)ON1C(N2[C@@H](C3=C([C@@H]1C2)C=NN3C)/C(/NC)=N/OS(=O)(=O)NC(OC(C)(C)C)=O)=O HCDHEWBZUSMJNL-WMZOPIPTSA-N 0.000 description 1
- AOCSUUGBCMTKJH-UHFFFAOYSA-N tert-butyl n-(2-aminoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCN AOCSUUGBCMTKJH-UHFFFAOYSA-N 0.000 description 1
- JRLJOAREDJOYLW-UHFFFAOYSA-N tert-butyl n-(2-aminooxyethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCON JRLJOAREDJOYLW-UHFFFAOYSA-N 0.000 description 1
- GPTXCAZYUMDUMN-UHFFFAOYSA-N tert-butyl n-(2-hydroxyethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCO GPTXCAZYUMDUMN-UHFFFAOYSA-N 0.000 description 1
- LIYMTLVBAVHPBU-UHFFFAOYSA-N tert-butyl n-(4-hydroxybutyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCCO LIYMTLVBAVHPBU-UHFFFAOYSA-N 0.000 description 1
- UZRUVUYVHGPEAP-UHFFFAOYSA-N tert-butyl n-(methylamino)carbamate Chemical compound CNNC(=O)OC(C)(C)C UZRUVUYVHGPEAP-UHFFFAOYSA-N 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762502867P | 2017-05-08 | 2017-05-08 | |
| US62/502,867 | 2017-05-08 | ||
| PCT/US2018/031593 WO2018208769A1 (en) | 2017-05-08 | 2018-05-08 | Compounds and methods for treating bacterial infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200005586A KR20200005586A (ko) | 2020-01-15 |
| KR102611447B1 true KR102611447B1 (ko) | 2023-12-06 |
Family
ID=62223332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197035865A Active KR102611447B1 (ko) | 2017-05-08 | 2018-05-08 | 박테리아 감염을 치료하는 화합물 및 방법 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US11046694B2 (enExample) |
| EP (1) | EP3630111B1 (enExample) |
| JP (1) | JP7058322B2 (enExample) |
| KR (1) | KR102611447B1 (enExample) |
| CN (1) | CN110709081B (enExample) |
| AU (1) | AU2018266640B2 (enExample) |
| CA (1) | CA3059773A1 (enExample) |
| CY (1) | CY1125340T1 (enExample) |
| DK (1) | DK3630111T3 (enExample) |
| EA (1) | EA038393B1 (enExample) |
| ES (1) | ES2907858T3 (enExample) |
| HR (1) | HRP20220231T1 (enExample) |
| HU (1) | HUE057592T2 (enExample) |
| IL (1) | IL270380B (enExample) |
| LT (1) | LT3630111T (enExample) |
| MA (1) | MA48743A (enExample) |
| MX (1) | MX385203B (enExample) |
| MY (1) | MY201377A (enExample) |
| PE (1) | PE20200333A1 (enExample) |
| PH (1) | PH12019502509A1 (enExample) |
| PL (1) | PL3630111T3 (enExample) |
| PT (1) | PT3630111T (enExample) |
| SG (1) | SG11201909443YA (enExample) |
| SI (1) | SI3630111T1 (enExample) |
| SM (1) | SMT202200110T1 (enExample) |
| TW (1) | TWI791018B (enExample) |
| WO (1) | WO2018208769A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3833665T3 (da) | 2018-08-09 | 2023-10-09 | Antabio Sas | Diazabicyclooctanoner som hæmmere af serin-beta-lactamaser |
| US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
| CN111675641B (zh) * | 2020-06-04 | 2023-09-08 | 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） | 单环β-内酰胺类化合物、单环内酰胺类化合物盐及其制备方法 |
| EP4146651A4 (en) | 2021-05-07 | 2024-06-05 | Ningxia Academy of Agriculture and Forestry Sciences | SULFONYLAMIDINE SUBSTITUTED COMPOUNDS AND THEIR USE AS BETA-LACTAMASE INHIBITORS |
| US11814385B2 (en) | 2021-06-25 | 2023-11-14 | University Of South Florida | Small molecule inhibitors targeting Clostridioides difficile sporulation |
| WO2025064681A1 (en) * | 2023-09-19 | 2025-03-27 | Entasis Therapeutics Inc. | Compounds and methods for treating bacterial infections |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090018329A1 (en) | 2002-12-06 | 2009-01-15 | Novexel | Novel heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors |
| WO2014141132A1 (en) | 2013-03-14 | 2014-09-18 | Naeja Pharmaceutical Inc. | NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995018129A1 (en) | 1993-12-29 | 1995-07-06 | Pfizer Inc. | Diazabicyclic neurokinin antagonists |
| FR2812635B1 (fr) | 2000-08-01 | 2002-10-11 | Aventis Pharma Sa | Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens |
| FR2825705B1 (fr) | 2001-06-08 | 2005-05-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens |
| FR2835186B1 (fr) | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
| FR2848210B1 (fr) * | 2002-12-06 | 2007-10-19 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases |
| US7507727B2 (en) * | 2003-04-07 | 2009-03-24 | Cylene Pharmaceuticals, Inc. | Substituted quinobenzoxazine analogs and methods of using thereof |
| FR2914923B1 (fr) | 2007-04-12 | 2013-06-14 | Novexel | Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens. |
| JP5038509B2 (ja) | 2008-01-18 | 2012-10-03 | メルク・シャープ・エンド・ドーム・コーポレイション | β−ラクタマーゼ阻害剤 |
| FR2930553B1 (fr) | 2008-04-29 | 2010-05-21 | Novexel | Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases |
| EP2135959A1 (en) | 2008-06-19 | 2009-12-23 | Novexel | Use of (1R,2S,5R) 1,6-Diazabicyclo [3,2,1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases |
| FR2936798B1 (fr) | 2008-10-03 | 2012-09-28 | Novexel | Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens. |
| FR2936951B1 (fr) | 2008-10-10 | 2010-12-03 | Novexel | Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments |
| FR2937034B1 (fr) * | 2008-10-10 | 2012-11-23 | Novexel | Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens |
| FR2951171A1 (fr) | 2009-10-09 | 2011-04-15 | Novexel | Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation |
| AU2011373912B2 (en) | 2011-07-26 | 2016-09-29 | Wockhardt Limited | Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor |
| JP5808860B2 (ja) | 2011-07-26 | 2015-11-10 | ウォックハート リミテッド | スルバクタム及びベータ−ラクタマーゼインヒビターを含む医薬組成物 |
| RU2636147C1 (ru) | 2011-08-27 | 2017-11-21 | Вокхардт Лимитед | Производные 1,6-диазабицикло[3,2,1]октан-7-она и их применение при лечении бактериальных инфекционных болезней |
| AU2012303693B2 (en) * | 2011-08-30 | 2014-07-03 | Wockhardt Limited | 1,6- diazabicyclo [3,2,1] octan- 7 - one derivatives and their use in the treatment of bacterial infections |
| US8754102B2 (en) | 2011-09-13 | 2014-06-17 | Wockhardt Ltd. | Nitrogen containing compounds and their use |
| US8796257B2 (en) | 2011-12-02 | 2014-08-05 | Naeja Pharmaceutical Inc. | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors |
| EP2814483A2 (en) | 2012-02-15 | 2014-12-24 | Rempex Pharmaceuticals, Inc. | Methods of treating bacterial infections |
| US8916709B2 (en) | 2012-03-30 | 2014-12-23 | Cubist Pharmaceuticals, Inc. | 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors |
| AU2013237869A1 (en) | 2012-03-30 | 2014-10-23 | Cubist Pharmaceuticals, Inc. | Isoxazole beta-lactamase inhibitors |
| US8969570B2 (en) | 2012-03-30 | 2015-03-03 | Cubist Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| WO2013149121A1 (en) | 2012-03-30 | 2013-10-03 | Cubist Pharmaceuticals, Inc. | 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors |
| AR090539A1 (es) | 2012-04-02 | 2014-11-19 | Astrazeneca Ab | COMPUESTOS INHIBIDORES DE b LACTAMASA |
| TWI565707B (zh) | 2012-05-30 | 2017-01-11 | 明治製菓藥業股份有限公司 | 新穎β－內醯胺酶抑制劑及其製造方法 |
| EP2961751B1 (en) | 2012-08-25 | 2018-03-21 | Wockhardt Limited | 1,6- diazabicyclo [3,2,1]octan- 7- one derivatives and their use in the treatment of bacterial infections |
| CN104768547A (zh) | 2012-09-03 | 2015-07-08 | 沃克哈特有限公司 | 抗菌组合物 |
| CA2897446A1 (en) | 2013-02-06 | 2014-08-14 | Astrazeneca Ab | Combination therapy for the treatment of nosocomial pneumonia |
| US9968593B2 (en) | 2014-11-17 | 2018-05-15 | Entasis Therapeutics Limited | Combination therapy for treatment of resistant bacterial infections |
| SMT202200397T1 (it) | 2016-09-16 | 2022-11-18 | Entasis Therapeutics Ltd | Composti inibitori di beta-lattamasi |
-
2018
- 2018-05-08 PT PT187267026T patent/PT3630111T/pt unknown
- 2018-05-08 TW TW107115559A patent/TWI791018B/zh active
- 2018-05-08 IL IL270380A patent/IL270380B/en unknown
- 2018-05-08 HR HRP20220231TT patent/HRP20220231T1/hr unknown
- 2018-05-08 SI SI201830571T patent/SI3630111T1/sl unknown
- 2018-05-08 SG SG11201909443Y patent/SG11201909443YA/en unknown
- 2018-05-08 HU HUE18726702A patent/HUE057592T2/hu unknown
- 2018-05-08 PE PE2019002309A patent/PE20200333A1/es unknown
- 2018-05-08 PL PL18726702T patent/PL3630111T3/pl unknown
- 2018-05-08 CN CN201880030289.8A patent/CN110709081B/zh active Active
- 2018-05-08 EP EP18726702.6A patent/EP3630111B1/en active Active
- 2018-05-08 WO PCT/US2018/031593 patent/WO2018208769A1/en not_active Ceased
- 2018-05-08 US US16/611,065 patent/US11046694B2/en active Active
- 2018-05-08 CA CA3059773A patent/CA3059773A1/en active Pending
- 2018-05-08 AU AU2018266640A patent/AU2018266640B2/en active Active
- 2018-05-08 MY MYPI2019006163A patent/MY201377A/en unknown
- 2018-05-08 DK DK18726702.6T patent/DK3630111T3/da active
- 2018-05-08 MX MX2019013291A patent/MX385203B/es unknown
- 2018-05-08 ES ES18726702T patent/ES2907858T3/es active Active
- 2018-05-08 KR KR1020197035865A patent/KR102611447B1/ko active Active
- 2018-05-08 SM SM20220110T patent/SMT202200110T1/it unknown
- 2018-05-08 JP JP2020512769A patent/JP7058322B2/ja active Active
- 2018-05-08 LT LTEPPCT/US2018/031593T patent/LT3630111T/lt unknown
- 2018-05-08 EA EA201992370A patent/EA038393B1/ru unknown
- 2018-05-08 MA MA048743A patent/MA48743A/fr unknown
-
2019
- 2019-11-08 PH PH12019502509A patent/PH12019502509A1/en unknown
-
2022
- 2022-02-23 CY CY20221100157T patent/CY1125340T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090018329A1 (en) | 2002-12-06 | 2009-01-15 | Novexel | Novel heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors |
| WO2014141132A1 (en) | 2013-03-14 | 2014-09-18 | Naeja Pharmaceutical Inc. | NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102611447B1 (ko) | 박테리아 감염을 치료하는 화합물 및 방법 | |
| EP3426248B1 (en) | Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections | |
| ES2776654T3 (es) | Composición farmacéutica para administración oral que comprende un modulador de P2X7 | |
| AU2011311867A1 (en) | Furo(3,2-d)pyrimidine compounds | |
| KR20160141770A (ko) | 항균 화합물 | |
| KR20180066264A (ko) | 세펨 화합물, 그의 제조 및 용도 | |
| EP2758376A1 (en) | Heterocyclic compounds as inhibitors of fatty acid biosynthesis for bacterial infections | |
| WO2014072930A2 (en) | Fused pyridine derivatives as antibacterial agents | |
| WO2017046605A1 (en) | Antibacterial compounds | |
| WO2018129008A1 (en) | Compounds and methods for treating bacterial infections | |
| HK40026676B (en) | Compounds and methods for treating bacterial infections | |
| CN107108646A (zh) | 阿根诺卡菌素类化合物及其作为抗菌剂的用途 | |
| WO2017137742A1 (en) | Antibacterial compounds | |
| WO2017046603A1 (en) | Antibacterial compounds and new uses thereof | |
| US10487093B2 (en) | Heterocyclic compounds, in particular 2-oxo-4,4,5,5,6,6,7,7-octahydrobenzoxazole derivatives, and their use as antibacterial compounds | |
| WO2016024096A1 (en) | Antibacterial compounds | |
| BR112019023130B1 (pt) | Compostos antibacterianos, composição farmacêutica que os compreende, e usos dos mesmos | |
| WO2017046606A1 (en) | Antibacterial compounds | |
| US20250282785A1 (en) | Pyrrolidinone derivatives as inhibitors of nf kappa b inducing kinase | |
| WO2017137743A1 (en) | Antibacterial compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20191204 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20210507 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230629 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20230913 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20231204 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20231204 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |